EPCAM and kidney cancer: In turn, in the 15 WT (out of 17 malignant kidney tumors analyzed) samples, neoplastic cells co-expressed CD9, CD81, and CD271 in the absence of HLADR and GD2, usually in the context of an EpCAM+ (13/15, 86%) phenotype.